the good and And afternoon Thanks, Lynn. thanks call. for everyone joining
As you in off to you'll hear ways. to encourage today, start XXXX. measure two I'd we're a great us in
the to fronts made against we've both R&D happy and our progress expectations I'm we report that First, second, our met performance; quarter. term near and programs. and this quarterly on clinical exceeded
approvals, series market portfolio, while enhancements. we same drive calls introductions we to current and growth from new work of consistent product from time earnings recall our the previous product that may towards a You at expect
of the change potential these the to of profile dramatically Some company. growth initiatives the have
the will Mark approval strong CE two, growth in graft; for we we detail we submitted of completed PerClot branch regulatory four, organic Our ability submitted we enrollment once achieve E-nside clinical simultaneously the on milestones for the development one, throughout illustrates our and submitted and U.S. I BioGlue stent these revenue including: E-nya in for trial; key three, again touch graft. produce each to thoracic call. stent the first more quarter thoracoabdominal China;
total Regarding year-over-year $XX.X to XXXX our revenue JOTEC of was consistent non-GAAP constant million, This first growth, on product basis lines. on strong primarily driven the reflecting quarter growth revenue the growth and a On-X for quarter X% relative a basis. GAAP currency organic was XX% of and by
a on quarter to as relative product For the on a of and basis quarter XX% constant to the currency non-GAAP XX% market JOTEC share. line GAAP first basis, take grew continues XXXX, JOTEC our
stent XXXX aortic We're continue competition. We this of throughout also offer out product a the grafts stand abdominal to aorta ascending given full covering trend expect through the suite from the our JOTEC to company only aorta. the how
expect We markets key into products to JOTEC international year. introduce of end by next-generation the three new the
constant currency our a non-GAAP North On-X, to growing revenue on constant relative revenues of quarter on On-X first in and increased XX% a to currency basis, XX%. non-GAAP XX% first XXXX GAAP Turning quarter basis the with America
trial X.X surgery conduct we We INR would regulatory successful period for of an of is to FDA considerable stronger the have a initial as On-X valves. months than that world a approval. be managed to replicated label, a the clinical allowing it first is and this in of to advantage the mechanical believe expect three competitor’s by quarter, remain valve growth in were be lower compared in it the level level their our gross only an take markets. our from to and slightly to anticipated, aortic future, cost the for beat unlikely revenue given revenue continue at the competitor margins mix We overall obtain the X.X, to distributor revenue carries better it Despite solid our to will mechanical patients X.X INR driven than expected competitive our aortic as by after to X.X time
our first quarter performance review JOTEC, in some to Starting detail and introduce like outlook business now I the XXXX more call. growth in will with well to as Ashley financial track near on we're and long-term discuss our recent of would catalysts. as later submitted we stent ever off-the-shelf products called thoracic be anticipate three approved E-nya this we graft markets in CE thoracoabdominal new This Mark, past in in both branch device summer. JOTEC XXXX. select our which international of E-nside will later for quarter first next-generation called highlights,
of the that for a for as E-vita goal we Open with patient-specific the be off-the-shelf, to summer device Trunk time Neo, Mark of surgeons, on branch this both first will next-generation eliminating Further, patients confident regulatory CE custom offer graph branch are our benefits days a our and this will the available graph remain track built. waiting be to stent a Elephant Frozen will be thoracoabdominal receiving by thus end submit We of approval the year. called of ability meaningful for
we Moving in BioGlue Chinese regulatory for to approval the the first quarter. FDA submitted to BioGlue,
As keep available. in what take when two process, on will this as you through visibility a we’ll we updated reminder, but progress years. to approval know We cycle the China do go can up the be not
in addition, U.S. we complete In trial our report to enrollment pleased that for we're clinical PerClot.
to approval PMA in potential submit FDA in XXXX coming a XXXX. We early with later our expect
experience. large expanding and reach, we've new which medtech Asia-Pacific operations our with begun sales Regarding two commercial our global company with of in America leaders, both Latin our come extensive
we'll be Over America. migrate many and selectively We the makes eight Latin of these regions quarters, direct and a financial it model in we'll people adding currently sales use to sense. in Asia-Pacific ten next in distributors towards where people approximately XX several
acquired BioGlue we them. territories, in before moves direct to process able migrated these the sales our experience direct the on and when European the in expect to Based as produce sales operations begin in place consistent are by results. gain that will we leverage success On-X we to going in of regions were with we example, Brazil, in and to strong we direct For direct and JOTEC existing put
I would our valve like On-X mechanical Finally, and discuss tissue to business.
presented the we driving we the Stelzer's On our on tissue solid is business, to positive be growth that Paul procedure long-term valves. continuous this be study based pulmonary and later are results. which of positive data stream the Dr. these the tissue this in data over will read incremental out believe Adding Ross week meeting the tissue dataset forward looking will in the valve will tissue Dr. side, Toronto. results great performed of our performance confident to AATS procedure that growth in continue business. in Annual patients with Stelzer the at we're to success those We're drive valve of pulmonary Ross on XXX
then As pulmonary procedure the Ross is valve, replace reminder, which aortic to patient's double to a position. a valve is operation the used native is the their where allograft moved pulmonary
valve, Moving this FDA we'll We currently finalize to with FDA leg the of needed to what our our an the On-X long-term for PROACT is next we from IND growth summer. that anticipate are approved best-in-class trial. the have working mechanical for XXA
data and would like the XXXX our and the At factored of level on with and have to this Before TAVR term announced closing, something thoughts III a business. business. PARTNER recently we've I into On-X on both guidance you longer been is high our our that its future my potential impact expecting share
will closer So valves a currently, in age implanted Ashley. we On-X standpoint, a of in to the two devices and old. opportunity average believe the patients was to do market the a material that, years target With the actually population over expect increase mutually III XXA that population PARTNER’s this I turn to is generally also patient not We XX years And old. now will in for patient will impact. age population being the age two of up data time old. treated trial the From call PROACT patient average the the devices. We years the XX XX by With with but On-X change XX, an population we valve TAVR that in over implanted target be exclusive. expect patients On-X is remain positive believe for these be will will for
